Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT07316127

Immunoadsorption in Autoimmune Long COVID

Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2026-01-05

70

Participants Needed

1

Research Sites

114 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake. This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months. This research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.

CONDITIONS

Official Title

Immunoadsorption in Autoimmune Long COVID

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Long COVID based on the WHO-criteria
  • Post-exertional malaise (PEM) according to the DSQ-PEM
  • BELL's functionality score between 20% and 70%
  • Good health before the long COVID diagnosis (WHO performance score 0)
Not Eligible

You will not qualify if you...

  • History of significant respiratory or cardiovascular disease
  • Cardiac interventional procedure within 3 months before randomization
  • Current immunosuppressive treatment for systemic autoimmune disorders
  • Type 1 diabetes
  • Solid organ cancer in the past 5 years
  • Active psychiatric disorder under psychiatric treatment
  • Body mass index over 35
  • Fatigue existing before long COVID
  • Poor performance score before long COVID diagnosis (WHO performance score above 0)
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

AUMC

Amsterdam, Netherlands

Actively Recruiting

Loading map...

Research Team

D

Daphne Schouten, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Immunoadsorption in Autoimmune Long COVID | DecenTrialz